SecBot SecBot

PMCB

PharmaCyte Biotech, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. NV· CIK 0001157075 Biotech & Drug Discovery
$0.3501 −0.01 (−1.44%)
Oct 26 4:00 PM ET · prev $0.3552
Market cap
$3.8M
Nano cap
1 year
−64.5%
from $0.9870 · Oct 27
30 days
−16.6%
from $0.4199
52-week range
$0.3402–1.22
−71% from high · low Oct 16
Avg volume 20D
81.8K
Oct 6 spike 232.1K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
1
analyzed by SecBot
SecBot read BEARISH 1 report · 90 days
Balance 1 bearish · 0 bullish oldest → newest, height = score
Avg score
Strongest BEARISH PharmaCyte Biotech dismissed its auditor, CBIZ CPAs, and engaged Grassi & Co. as its new independent…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • X Aug 14 Short interest falls 28.7% to 208.2K
  • X Aug 31 Short interest falls 61.7% to 79.8K
  • X Sep 30 Short interest jumps 90.1% to 133.9K

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 3 added (0 new), 4 trimmed or exited.

  • TrendDOWNTREND

    20% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM124,247$95.7K
RENAISSANCE TECHNOLOGIES LLCTRIM37,987$29.3K
JANE STREET GROUP, LLCDOUBLED30,064$23.1K
COMMONWEALTH EQUITY SERVICES, LLCADD20,255$15.6K
HRT FINANCIAL LPTRIM15,451$11.0K
GROUP ONE TRADING LLCTRIM500$385.00
MORGAN STANLEYDOUBLED2$2.00
GEODE CAPITAL MANAGEMENT, LLCADD195,660$130.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Nov 2021
Recent actions
DateFirmActionRating
Nov 8, 2021HC Wainwright & Co.
INITIATE
INITIATENeutral

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Mar 31, 2026
Abecassis Michael M
Director
OTHER0 sh
Mar 31, 2026
WEINSTEIN ROBERT
Director
OTHER0 sh
Mar 31, 2026
SCHECHTER JONATHAN
Director
AWARD119,170 sh
Mar 31, 2026
Abecassis Michael M
Director
AWARD119,170 sh
Mar 31, 2026
WEINSTEIN ROBERT
Director
AWARD119,170 sh
Mar 31, 2026
WALKER WAYNE REMELL
Director
AWARD119,170 sh
Mar 31, 2026
WALKER WAYNE REMELL
Director
OTHER0 sh
Mar 31, 2026
SCHECHTER JONATHAN
Director
OTHER0 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 SEC
PharmaCyte Biotech dismissed its auditor, CBIZ CPAs, and engaged Grassi & Co. as its new independent registered public…
8-K — Impact 5/10
Sep 14, 2026 Earnings calendar
PMCB Q1 2027 Earnings Scheduled — 2026-09-14
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
124,247 shares ($95.7K)
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
37,987 shares ($29.3K)
Mar 31, 2026 Insider
Abecassis Michael M acquired 0 shares
Director
Mar 31, 2026 Insider
WEINSTEIN ROBERT acquired 0 shares
Director
Mar 31, 2026 Insider
SCHECHTER JONATHAN was granted 119,170 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 14, 2026
Earnings date
PMCB Q1 2027 Earnings Scheduled — 2026-09-14
Sep 4, 2026
Clinical Trial
Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)
Phase 3 · COMPLETED
Mar 16, 2026
Earnings date
PMCB Q3 2026 Earnings Scheduled — 2026-03-16

SecBot reports

1 filing · 0 bullish · 1 bearish
All PMCB filing & press-release reports (1)